Dr. Heather Maynard’s laboratory integrates synthetic polymers with naturally-derived biomolecules to treat and detect cancer. The group develops novel synthetic methods to make important classes of cancer therapeutics including protein- or siRNA-polymer conjugates. They also focus on delivery of small molecule cancer drugs from nanocapsules. In addition, they develop diagnostics for the early detection of cancer. Maynard's approach involves many disciplines including polymer chemistry, biochemistry, and nanofabrication.
Selected Cancer-Related Publications:
Gunasekaran K, Nguyen TH, Maynard HD, Davis TP, Bulmus V. Conjugation of siRNA with comb-type PEG enhances serum stability and gene silencing efficiency. Macromol Rapid Commun. 2011 Apr 19;32(8):654-9. Epub 2011 Mar 17
Stukel JM, Li RC, Maynard HD, Caplan MR. Two-step synthesis of multivalent cancer-targeting constructs. Biomacromolecules. 2010 Jan 11;11(1):160-7.
Tao L, Kaddis CS, Ogorzalek Loo RR, Grover GN, Loo JA, Maynard HD. Synthetic approach to homodimeric protein-polymer conjugates. Chem Commun (Camb). 2009 Apr 28(16):2148-50. Epub 2009 Mar 18